Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical VDO for Herpes Simplex Labialis
NCT02207881Phase 2Completed
- Sponsor
- Yung Shin Pharmaceutical Industry
- Start
- Jul 2014
- Primary completion
- Dec 2015
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of diclofenac and lidocaine 10% oropharyngeal spray in herpes labialis (2 arms), sponsored by Yung Shin Pharmaceutical Industry. Primary endpoint: Adverse event up to 10 days. Started Jul 2014; status: completed.
02
Drugs
diclofenaclidocaine 10% oropharyngeal spray
03
Conditions
herpes labialis
Beyond the preview
Go deeper on NCT02207881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02207881.